Follow this preprint
Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson’s disease
View ORCID ProfileKatheryn A.Q. Cousins, View ORCID ProfileDavid J. Irwin, View ORCID ProfileThomas F. Tropea, Emma Rhodes, View ORCID ProfileJeffrey S. Phillips, View ORCID ProfileAlice S. Chen-Plotkin, View ORCID ProfileMichael C. Brumm, Christopher S. Coffey, Ju Hee Kang, View ORCID ProfileTanya Simuni, View ORCID ProfileTatiana Foroud, Arthur W. Toga, Caroline M. Tanner, Karl Kieburtz, Brit Mollenhauer, Douglas R. Galasko, View ORCID ProfileSamantha Hutten, View ORCID ProfileDaniel Weintraub, View ORCID ProfileAndrew Siderowf, Kenneth Marek, Gwendlyn Kollmorgen, View ORCID ProfileKathleen L. Poston, Leslie M. Shaw, The Parkinson’s Progression Marker Initiative
doi: https://doi.org/10.1101/2023.04.21.23288930
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Katheryn A.Q. Cousins
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania
PhDDavid J. Irwin
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania
MDThomas F. Tropea
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania
DOEmma Rhodes
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania
PhDJeffrey S. Phillips
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania
PhDAlice S. Chen-Plotkin
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania
MDMichael C. Brumm
2Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
MSChristopher S. Coffey
2Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
PhDJu Hee Kang
3Department of Pharmacology & Clinical Pharmacology, Inha University, Incheon, South Korea
PhDTanya Simuni
4Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
MDTatiana Foroud
5Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA
PhDArthur W. Toga
6Laboratory of Neuro Imaging, University of Southern California, Los Angeles, CA, USA
PhDCaroline M. Tanner
7Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
MD PhDKarl Kieburtz
8Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
MD MPHBrit Mollenhauer
9Department of Neurology, University Medical Center, Göttingen, Paracelsus-Elena-Klinik, Kassel and Scientific Employee with an Honorary Contract at German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany
MDDouglas R. Galasko
10Department of Neurology, University of California San Diego, San Diego, CA, USA
MDSamantha Hutten
11The Michael J. Fox Foundation, New York, NY, USA
PhDDaniel Weintraub
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania
12Department of Psychiatry Perelman, School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
13Michael J. Crescenz VA Medical Center, Parkinson’s Disease Research, Education, and Clinical Center, Philadelphia, PA, USA
MDAndrew Siderowf
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania
MDKenneth Marek
14Institute for Neurodegenerative Disorders, New Haven, CT, USA
MDGwendlyn Kollmorgen
15Roche Diagnostics GmbH, Penzberg, Germany
Kathleen L. Poston
16Department of Neurology, Stanford University, Palo Alto, CA, USA
MD MSLeslie M. Shaw
17Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
PhD
Data Availability
Data contained in this study were obtained from the PPMI database and are available upon request at www.ppmi-info.org.
Posted April 23, 2023.
Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson’s disease
Katheryn A.Q. Cousins, David J. Irwin, Thomas F. Tropea, Emma Rhodes, Jeffrey S. Phillips, Alice S. Chen-Plotkin, Michael C. Brumm, Christopher S. Coffey, Ju Hee Kang, Tanya Simuni, Tatiana Foroud, Arthur W. Toga, Caroline M. Tanner, Karl Kieburtz, Brit Mollenhauer, Douglas R. Galasko, Samantha Hutten, Daniel Weintraub, Andrew Siderowf, Kenneth Marek, Gwendlyn Kollmorgen, Kathleen L. Poston, Leslie M. Shaw, The Parkinson’s Progression Marker Initiative
medRxiv 2023.04.21.23288930; doi: https://doi.org/10.1101/2023.04.21.23288930
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (418)
- Allergy and Immunology (741)
- Anesthesia (217)
- Cardiovascular Medicine (3189)
- Dermatology (269)
- Emergency Medicine (471)
- Epidemiology (13170)
- Forensic Medicine (18)
- Gastroenterology (882)
- Genetic and Genomic Medicine (5002)
- Geriatric Medicine (464)
- Health Economics (767)
- Health Informatics (3148)
- Health Policy (1118)
- Hematology (418)
- HIV/AIDS (989)
- Medical Education (465)
- Medical Ethics (122)
- Nephrology (512)
- Neurology (4750)
- Nursing (253)
- Nutrition (704)
- Oncology (2445)
- Ophthalmology (695)
- Orthopedics (273)
- Otolaryngology (335)
- Pain Medicine (317)
- Palliative Medicine (89)
- Pathology (525)
- Pediatrics (1269)
- Primary Care Research (541)
- Public and Global Health (7315)
- Radiology and Imaging (1643)
- Respiratory Medicine (957)
- Rheumatology (469)
- Sports Medicine (412)
- Surgery (528)
- Toxicology (67)
- Transplantation (227)
- Urology (196)